5 Minutes with Maria Gonzalez
20 May 2016
This International Clinical Trials Day (20th May) we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future. We've sat down with MIA's Clinical Trials Manager, Maria Gonzalez to discuss.
What does a Clinical Trials Manager do and how did you get here?
In my role I work with a team of highly dedicated and caring trial co-ordinators who are responsible for looking after our trial patients. I completed a degree in nursing at The University of Sydney and worked at Royal Prince Alfred Hospital before deciding to work in clinical trials in the hope that I may contribute to life-saving research. I have been at MIA for 6 years now.
What are clinical trials so important?
Clinical trials provide patients with access to unavailable new treatments and are also the vital step in making discoveries that will enable us to find a cure for melanoma. Clinical trials are also an opportunity for patients to receive very specialised care from clinical trial co-ordinators who are available at every step along the way to support patients and their families.
What do you find most rewarding about your work?
As a nurse I am most rewarded by making a difference in the lives of those suffering with cancer. It is a privilege to be part of a patient support network at MIA and also wonderful to share in the good news when a trial treatment is successful. Although we have made significant progress and the future is positive, it is important we keep working together to find the cure.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.